Clinical Trial

I.V. Selonabant in Healthy Adult Subjects

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous Selonabant in Healthy Adult Subjects Aged 18 to 30 Years
Protocol Amendment History 3 changes
critical Trial completed 2026-05-09
notable Primary completion moved earlier: 2026-08-25 -> 2026-05-06 2026-05-09
minor Completion moved earlier: 2026-08-25 -> 2026-05-06 2026-05-09
Trial Details
NCT Number NCT07211607
Lead Sponsor Anebulo Pharmaceuticals
Collaborators: National Institute on Drug Abuse (NIDA)
Conditions Healthy Volunteers
Enrollment 40 participants
Start Date 2025-09-22
Primary Completion 2026-05-06 (estimated)
Study Completion 2026-05-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-08